8-K: Vaxart Addresses Reverse Stock Split Proposal to Maintain Nasdaq Listing

Vaxart is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.

Summary

• Vaxart is proposing a reverse stock split to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
• The company's share price was $0.42 as of May 9, 2025.
• The proposed reverse stock split ratio is not less than 1-for-5 and not more than 1-for-50.
• The board of directors intends to select a ratio only high enough to resolve the Nasdaq deficiency.
• The company believes a share repurchase program is not a prudent use of capital at this time because they are not currently profitable.
• The company believes it is unlikely to continue trading on Nasdaq without a reverse stock split unless there is a sudden change in the stock price above $1.00.
• The company believes maintaining its Nasdaq listing is essential in supporting the company's overall strategy of progressing its clinical stage programs for COVID-19 and norovirus while continuing to advance its promising preclinical pipeline.
• The company has obtained non-dilutive funding in the form of its BARDA award as well as a smaller award from the Gates Foundation.
• The company will continue to explore both business development partnerships and non-dilutive funding options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company faces challenges with its share price, it is taking proactive steps to address the issue and maintain its Nasdaq listing. The company also highlights positive aspects such as non-dilutive funding and recommendations from proxy advisory firms.

Positives

• Maintaining the Nasdaq listing could increase market visibility and broaden investor appeal.
• The reverse stock split could enhance long-term value by increasing trading volume and facilitating future financing opportunities.
• The company has already obtained significant non-dilutive funding through BARDA and the Gates Foundation.
• Independent proxy advisory firms ISS and Glass Lewis recommend stockholders vote FOR the reverse stock split proposal.

Negatives

• The company's share price is below the Nasdaq minimum bid price requirement, necessitating the reverse stock split.
• The company is not currently profitable, making a share repurchase program imprudent.
• Delisting from Nasdaq could adversely affect the value of the securities and trading volume.
• Delisting from Nasdaq could lead to a cessation of research coverage by financial analysts.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could result in delisting.
• Delisting from Nasdaq could limit access to capital and reduce market visibility.
• Organic price appreciation depends on unpredictable factors such as clinical trial results, regulatory progress, and market sentiment.
• The company needs more time and/or more data to advance business development partnerships and non-dilutive funding options.

Future Outlook

Vaxart intends to regain compliance with Nasdaq's minimum bid price requirement through a reverse stock split. The company will continue to explore business development partnerships and non-dilutive funding options to enhance stockholder value.

Management Comments

• Vaxart prefers the requirement to be satisfied through appreciation of Vaxart's stock price.
• A reverse stock split is not an option that Vaxart prefers; however, we believe it is in the best interest of the Company and stockholders to maintain our Nasdaq listing.

Industry Context

Many biotechnology companies face challenges in maintaining Nasdaq listing compliance, especially during periods of market volatility or when clinical trial results are delayed or unfavorable. Reverse stock splits are a common mechanism used to address low share prices and avoid delisting.

Comparison to Industry Standards

• Other biotech companies facing similar challenges, such as delisting warnings from Nasdaq, have also implemented reverse stock splits.
• The specific ratio of the reverse stock split (1-for-5 to 1-for-50) is within the typical range seen in similar situations.
• Companies like Agenus and Ocugen have also faced similar delisting warnings from Nasdaq and have considered or implemented reverse stock splits to regain compliance.

Stakeholder Impact

• Shareholders will be impacted by the reverse stock split, owning fewer shares at a higher price per share.
• Maintaining the Nasdaq listing is expected to benefit shareholders by increasing market visibility and access to capital.
• Employees' stock options and equity awards will be adjusted accordingly.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the Annual Meeting on May 21, 2025.
• The board of directors will determine the final ratio for the reverse stock split if approved.
• The company will continue to explore business development partnerships and non-dilutive funding options.

Key Dates

Keywords

reverse stock split, Nasdaq, delisting, share price, compliance, Vaxart, stockholders, proxy, clinical trials, financing